Your browser doesn't support javascript.
loading
Synchronous bilateral breast cancer treated with a 3-week hypofractionated radiotherapy schedule: clinical and dosimetric outcomes
Gadea, J; Ortiz, I; Roncero, R; Alastuey, I; Mestre, F; Aymar, , N; Maturana, J. E; Garcia, C; Mateu, L; Pardo, J.
Afiliação
  • Gadea, J; Hospital Universitari Son Espases. Radiation Oncology Department. Palma de Mallorca. Spain
  • Ortiz, I; Hospital Universitari Son Espases. Radiation Oncology Department. Palma de Mallorca. Spain
  • Roncero, R; Hospital Universitari Son Espases. Radiation Oncology Department. Palma de Mallorca. Spain
  • Alastuey, I; Hospital Universitari Son Espases. Radiation Oncology Department. Palma de Mallorca. Spain
  • Mestre, F; Hospital Universitari Son Espases. Radiation Oncology Department. Palma de Mallorca. Spain
  • Aymar, , N; Hospital Universitari Son Espases. Radiation Oncology Department. Palma de Mallorca. Spain
  • Maturana, J. E; Hospital Universitari Son Espases. Radiation Oncology Department. Palma de Mallorca. Spain
  • Garcia, C; Hospital Universitari Son Espases. Radiation Oncology Department. Palma de Mallorca. Spain
  • Mateu, L; Hospital Universitari Son Espases. Radiation Oncology Department. Palma de Mallorca. Spain
  • Pardo, J; Hospital Universitari Son Espases. Radiation Oncology Department. Palma de Mallorca. Spain
Clin. transl. oncol. (Print) ; 23(9): 1915-1922, sept. 2021. ilus
Artigo em Inglês | IBECS | ID: ibc-222190
Biblioteca responsável: ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
Background and purpose Synchronous bilateral breast cancer (SBBC) accounts for 1–3.5% of breast cancer patients. The aim of this study was to evaluate dosimetric issues, clinical outcomes, and acute toxicities for SBBC patients receiving synchronous bilateral hypofractionated radiotherapy (SBHRT) and to compare them with patients treated with synchronous bilateral normofractionated RT schedule (SBNRT). Materials and methods From April 2016 to March 2020, 39 SBBC patients were referred to our institution. Patients were divided according to their prescription dose Group A 50 Gy/25fx (fractions), B 60–64 Gy/25fx, C 40.05 Gy/15fx; D 48 Gy/15fx. Toxicity was evaluated using Common Terminology Criteria for Adverse Events (CTCAE)v.5.0. Results 34 patients were finally evaluated. Median follow-up was 24 months for NF schedule and 9 months for HF schedule. In the HF schedule, no acute side-effects > G2 were observed and no dermatitis was reported in 6th month´s assessments. 95% of patients have no evidence of disease and only 1 patient presented local relapse in the first mammography after RT. No distant failures or deaths were observed. Regarding dosimetric issues, the inter-patient average Dmean for the heart was Group A 5.0 Gy (4.6–5.5), Group B 4.4 Gy (4.1–5.4), Group C 4.8 Gy (4.5–5.1) and Group D 5.3 Gy (4.4–5.6). For the lungs, the inter-patient average Dmean was Group A 10.8 Gy (9.8–12.2), Group B 11.5 Gy (11.3–12), Group C 9.8 Gy (9.3–10.5) and Group D 10.5 Gy (10–11.3). Conclusions This is the first study reporting the safety, feasibility, and tolerability of 40.05 Gy/15fx over 3 weeks for the treatment of SBBC patients. Further study with larger accrual is mandatory (AU)
Assuntos

Buscar no Google
Coleções: Bases de dados nacionais / Espanha Base de dados: IBECS Assunto principal: Neoplasias da Mama / Hipofracionamento da Dose de Radiação / Neoplasias Primárias Múltiplas Limite: Feminino / Humanos Idioma: Inglês Revista: Clin. transl. oncol. (Print) Ano de publicação: 2021 Tipo de documento: Artigo Instituição/País de afiliação: Hospital Universitari Son Espases/Spain
Buscar no Google
Coleções: Bases de dados nacionais / Espanha Base de dados: IBECS Assunto principal: Neoplasias da Mama / Hipofracionamento da Dose de Radiação / Neoplasias Primárias Múltiplas Limite: Feminino / Humanos Idioma: Inglês Revista: Clin. transl. oncol. (Print) Ano de publicação: 2021 Tipo de documento: Artigo Instituição/País de afiliação: Hospital Universitari Son Espases/Spain
...